SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001624422-23-000050
Filing Date
2023-10-25
Accepted
2023-10-25 09:21:10
Documents
4
Period of Report
2023-10-24

Document Format Files

Seq Description Document Type Size
1 6-K phxm_6-kx10242023.htm 6-K 20610
2 EX-99.1 ex-991phxm_6xkx10242023.htm EX-99.1 12286
3 EX-99.2 ex-992phxm_6xkx10242023.htm EX-99.2 20307
4 GRAPHIC image.jpg GRAPHIC 7189
  Complete submission text file 0001624422-23-000050.txt   64483
Mailing Address 60 AVENUE ROCKEFELLER BATIMENT ADENINE LYON I0 69008
Business Address 60 AVENUE ROCKEFELLER BATIMENT ADENINE LYON I0 69008 011-33-4-78-74-44-38
PHAXIAM Therapeutics S.A. (Filer) CIK: 0001624422 (see all company filings)

IRS No.: 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38281 | Film No.: 231344184
SIC: 2836 Biological Products, (No Diagnostic Substances)